A US emergency declaration published on 3 September 2026 allows FDA to consider drugs for moderate-to-severe acute pain in ...
• Maintain BUY with an unchanged PE-based target price of S$3.49, pegged to 25x 2026F PE or 2SD above the long-term average.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results